As of 30 Sep 2025, 42 institutional investors reported holding $627,523,074 in principal (par value) of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $22,220 | $1,160,296 | 5666.95% | 2 | |
| 2025 Q3 | $627,523,074 | $621,164,871 | -$32,618,402 | 98.82% | 42 |
| 2025 Q2 | $677,603,924 | $703,617,373 | -$10,235,499 | 93.59% | 41 |
| 2025 Q1 | $692,365,423 | $625,022,314 | +$61,677,589 | 90.0% | 41 |
| 2024 Q4 | $627,730,524 | $538,661,074 | -$2,449,192 | 85.63% | 38 |
| 2024 Q3 | $632,466,339 | $531,505,403 | -$6,333,183 | 83.62% | 38 |
| 2024 Q2 | $641,592,339 | $515,193,358 | -$50,159,208 | 80.13% | 42 |
| 2024 Q1 | $698,250,289 | $605,157,349 | -$20,634,889,530 | 81.94% | 41 |
| 2023 Q4 | $94,275,000 | $80,312,873 | 85.19% | 1 | |
| 2023 Q3 | $615,528,792 | $493,166,757 | +$43,964,188 | 75.01% | 44 |
| 2023 Q2 | $502,846,952 | $337,191,901 | +$7,892,433 | 61.76% | 40 |
| 2023 Q1 | $515,601,127 | $355,699,506 | -$7,128,615,789 | 63.92% | 43 |
| 2022 Q4 | $543,781,458 | $510,433,414 | -$1,152,000 | 38.56% | 35 |
| 2022 Q3 | $499,487,458 | $547,237,527 | -$37,561,511 | 43.59% | 33 |
| 2022 Q2 | $594,504,458 | $249,119,690 | -$25,981,556 | 40.87% | 34 |
| 2022 Q1 | $625,412,958 | $307,058,595 | +$297,596,875 | 47.61% | 36 |